medigraphic.com
ISSN 1560-4381 (Print)

2017, Number 3

<< Back Next >>

Correo Científico Médico 2017; 21 (3)

Clinical and immunogenic response of Heberón treatment in patients with basal cell carcinoma, Mario Gutiérrez Ardaya Polyclinic

Pérez LE, Brizuela NMY, Ortíz LJM

Language: Spanish
References: 39
Page: 834-857
PDF size: 698.98 Kb.


ABSTRACT

Introduction: Basal cell carcinoma is the most frequent skin neoplasm in white patients; Human recombinant interferon alpha 2b is a drug modifying the biological response currently used in the treatment of this disease.
Objective: To determine the clinical and immunogenic response of the Heberon in basal cell carcinoma.
Method: A therapeutic use trial involving 18 patients with the histological diagnosis of basothelioma was performed. The intervention consisted of the perilesional application of nine doses of the drug Heberón for a period of three weeks, followed by a biopsy for evolutionary puncture At 13 weeks after the treatment.
Results: At the conclusion of the treatment, 84.61% of the patients achieved the total disappearance of the lesion by clinical, dermatoscopic and histological criteria; 15.38% achieved a partial response, the quality of the healing was good and at one year of follow up the patients cured showed no recurrence of the tumor lesion. An advantage of this modality of treatment was the favorable clinical evolution of neoplastic and preneoplastic lesions at a distance. The most frequent adverse events observed with Heberón's use were fever 72.22%, chills 55.55%, edema and erythema 50.00%, myalgias 44.44%, arthralgia, pain at the injection site 33.33% And malaise 27,77% classified as mild and moderate according to their severity, as well as very probable according to their causality. Only 29.41% of the patients had anti-interferon antibodies.
Conclusions: Heberón is an effective, safe drug for the treatment of basal cell carcinoma with the use of this therapy may appear immunogenicity.


REFERENCES

  1. Sallyann KC, Chen S. Analyzing the Cost of Preventing Nonmelanoma Skin Cancer. J Invest Derm. 2009[citado 21 ene 2017]; 129(12):2745-2746. Disponible en: http://www.sciencedirect.com/science/article/pii/S0022202X15341713?via%3Dihub

  2. Lukaszuk BLM, Cidral Muniz E, Leite da Veiga M, Iribas JL. Aspectos epidemiológicos del cáncer no melanoma de piel en un servicio de dermatología de la ciudad de Santa Fe - Argentina 2007. Respuesta clínica e inmunogénica del tratamiento con Heberón en pacientes con carcinoma basal, Policlínico…853 Rev Argent Dermatol. 2008 [citado 8 jun 2017]; 89(1): 30-36. Disponible en: http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S1851-300X2008000100005&lng=es

  3. World Health Organization. From Australia to Brazil: sun worshippers beware. Bull World Health Organ. 2009[citado 8 jun 2017]; 87(8):574–575. Disponible en: www.who.int/entity/bulletin/volumes/87/8/09-030809.pdf

  4. Victoria Bárzaga HO. Métodos para la prevención y tratamiento del carcinoma basocelular. AMC. 2011[citado 21 ene 2011]; 15(2):212-213.Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-02552011000200001

  5. Victoria Bárzaga HO, Lazo Sánchez L. Relación clínico histopatológica de lesiones tumorales de la piel. AMC.2006 [citado 18 ene 2010]; 10(4):219-221. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-02552006000400009

  6. Cuba. Ministerio de Salud Pública. Anuario Estadístico de Salud. La Habana: MINSAP; 2016. Disponible en: http://files.sld.cu/dne/files/2017/05/Anuario_Estad%C3%ADstico_de_Salud_e_2016_edici%C3%B3n_2017.pdf

  7. Madan V, Hoban P, Strange RC, Fryer AA, Lear JT. Genetics and risk factors for basal cell carcinoma. Br J Dermatol. 2006[citado 8 jun 2017]; 154(supl1):5–7.Disponible en: http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2133.2006.07229.x/full

  8. Rodust PM, Stockfleth E, Ulrich C, Leverkus M, Eberle J. UV-induced squamous cell carcinoma: a role for antiapoptotic signalling pathways. Brit J Dermatol. 2009[citado 8 jun 2017]; 3(161):107-115. Disponible en: http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2133.2009.09458.x/full

  9. Buljan M, Bulat V, Situm M, Mihić LL, Stanić-Duktaj S. Variations in clinical presentation of basal cell carcinoma. Acta Clin Croat. 2008[citado 8 jun 2017]; 47(1):25-30. Disponible en: http://hrcak.srce.hr/25816

  10. Kirkham N. Tumors and Cysts of the epidermis. En: Elder DE, Elenitsas R, Johnson B, Jaworsky C. Lever´s histopathlogy of the skin. 9th ed. Philadelphia: Lippincott Wilkins; 2006.p.617-654

  11. Lamon T, Gerard S, Meyer N, Losfeld B, van Kan GA, Balardy L, et al. Exceptional bone metastasis of basal cell carcinoma in Gorlin-Goltz syndrome. Dermatology. 2010 [citado 8 jun 2017]; 220(1):57-59. Disponible en: https://www.karger.com/Article/FullText/264669

  12. Bin Yap FB. Clinical characteristics of basal cell carcinoma in a tertiary hospital in Sarawak, Malaysia. Int J Dermat. 2010[citado 8 jun 2017]; 49(2):176-179.Disponible en: http://onlinelibrary.wiley.com/doi/10.1111/j.1365-4632.2009.04342.x/epdf

  13. Bath Hextall FJ, Perkins W, Bong J, Williams HC. Intervenciones para el carcinoma basocelular de la piel. Cochrane Plus. 2013 [citado 22 ene 2016]; 5.Disponible en:http://www.bibliotecacochrane.com/BCPGetDocumentForPrint.asp?DocumentID=CD003412

  14. Aguayo Leiva IR, Ríos Bucetay L, Jaen Olasolo P. Tratamiento quirúrgico vs no quirúrgico en el carcinoma basocelular. Actas Dermo Sifiliogr.2010 [citado 22 ene 2016]; 101(8):683–692. Disponible en: http://www.sciencedirect.com/science/article/pii/S0001731010002796?via%3Dihub

  15. Galimberti G, Pontón Montaño A, Ferrario D, Kowalczuk A, Galimberti R. Cirugía micrográfica de Mohs en el tratamiento de carcinoma basocelular. Actas Dermo Sifiliogr. 2010[citado 22 ene 2016]; 101 (10): 853-857. Disponible en:http://www.sciencedirect.com/science/article/pii/S0001731010003352?via%3Dihub

  16. Love WE, Bernhard JD, Bordeaux JS. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. Arch Dermatol. 2009[citado 22 ene 2016]; 145(12):1431-1438. http://jamanetwork.com/journals/jamadermatology/fullarticle/712288

  17. Isaacs A, Lindenmann J. Virus Iterference .I. The Interferon. Proc R Soc Lond B Biol Sc.1957 [citado 12 nov 2015]; 147(927):258-263.Disponile en: http://rspb.royalsocietypublishing.org/content/147/927/258

  18. Ross C, Tingsgaard P, Jorgensen H, Vejlsgaard GL. Interferon treatment of cutaneous T-cell lymphoma. Eur J Haematol. 1993[citado 12 nov 2015]; 51(2):63-72. http://onlinelibrary.wiley.com/doi/10.1111/j.1600-0609.1993.tb01595.x/full

  19. García García I, González Delgado CA, Valenzuela Silva C, Hernández Bernal F, Ferrero-Bibilonia J, Soto Hernández R, et al. Bioequivalence of two recombinant interferon alpha-2b liquid formulations in healthy male volunteers. Drugs RD. 2004[citado 12 nov 2015]; 5(5): 271-280.Disponible en: https://link.springer.com/article/10.2165/00126839-200405050-00003

  20. Stewart WE. The interferon system. New York: Springer-Verland Wien; 1980.

  21. Darnell JE, Kerr IM, Stark GR. JaK-Stat Pathways and transcriptional activation in response to interferons and other extracellular signaling proteins. Science. 1995[citado 12 nov 2015];264(5164):1415-1421.Disponible en: http://search.proquest.com/openview/e4cca120f2e48ad3d6edeb9971a818fb/1?pq-origsite=gscholar&cbl=1256

  22. Ruiz L, Reyes N, Aroche K, Báez R, Aldana R, Hardy E. Some factors affecting the stability of interferon alpha 2b in solution. Biologicals. 2006[citado 12 nov 2015]; 34(1):15-19. Disponible en: http://www.sciencedirect.com/science/article/pii/S1045105605000758?via%3Dihub

  23. Pérez E, Batista K, Guerra O, Bello I, Serrano MV. Interferones una opción terapéutica moderna en el tratamiento de los carcinomas basocelulares. CCM. 2016[citado 15 dic 2016]; 20(2). Disponible en: http://scielo.sld.cu/pdf/ccm/v20n2/ccm06216.pdf

  24. Buechner S, Wernli M, Bachmann F, Harr T, Erb P. Intralesional interferon in basal cell carcinoma: how does it work? Recent Results Cancer Res. 2002[citado 15 dic 2016]; 160: 246-250. Disponible en: https://link.springer.com/chapter/10.1007/978-3-642-59410-6_29

  25. Fenton S, Kennedy S, Moriarty P. The role of interferon alpha 2b as an adjunctive treatment in the management of aggressive basal cell carcinoma of the eyelids. Acta Ophthalmol Scand. 2002[citado 15 dic 2016]; 80(6):674-675. Disponible en: http://onlinelibrary.wiley.com/doi/10.1034/j.1600-0420.2002.800623_3.x/full

  26. Cornell RC, Greenway HT, Tucker SB, Edwards L, Ashworth S, Vance JC, et al. Intralesional interferon therapy for basal cell carcinoma. J Am Acad Dermatol. 1990[citado 15 dic 2016]; 23(4 Pt 1):694-700. Disponible en: http://www.sciencedirect.com/science/article/pii/019096229070276N?via%3Dihub

  27. Rogozinski TT, Jablonska S, Brzoska J, Michalska I, Wohr C, Gaus W. Intralesional treatment with recombinant interferon beta is an effective alternative for the treatment of basal cell carcinoma. Double-blind, placebo-controlled study. Przeglad Dermatologiczny. 1997; 84(3):259-263.

  28. Alpsoy E, Yilmaz E, Basaran E, Yazar S. Comparison of the effects of intralesional interferon alfa-1a, 2b and the combination of 2a and 2b in the treatment of basal cell carcinoma. J Dermatology. 1996[citado 15 dic 2016]; 23(6):394-396.Disponible en: http://onlinelibrary.wiley.com/doi/10.1111/j.1346-8138.1996.tb04040.x/full

  29. Edwards L, Tucker SB, Perednia D, Smiles KA, Taylor EL, Tanner DJ, et al. The effects of an intralesional sustained-release formulation of interferon alfa-2b on basal cell carcinoma. Arch Dermatol. 1990; 126(8):1029-1032.

  30. Anasagasti Angulo L, Garcia Vega Y, Barcelona Perez S, López Saura P, Bello Rivero I. Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study. BMC Cancer. 2009[citado 15 dic 2016]; 9:262. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2724551/

  31. Guijo Hernández T, Rodríguez Benítez A, Sánchez de la Orden C, Fernández Rosa S, Rodríguez Cabillas ME. Utilización de los criterios RECIST en el seguimiento de tumores sólidos. (31 Congreso nacional Sociedad española de radiología médica) 25-28 Mayo 2012; Granada.

  32. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). U.S.Department of Health And Human Services.2010 [citado 12 jun 2017].Disponible en: https://searchworks.stanford.edu/view/9100287

  33. OMS. Buenas prácticas de fármaco-vigilancia para las américas. Buenas Prácticas de Farmaco-vigilancia para las Américas.2008 [citado 22 Jun 2017].Disponible en:http://www.paho.org/hq/dmdocuments/2008/3_GT_VConfernecia_Farmacovigilancia.pdf

  34. Tucker SB, Polasek JW, Perri AI, Goldsmith EA. Long-term follow-up of basal cell carcinomas treated with perilesional interferon alfa 2b as monotherapy. JAAD.2006 [citado 7 mar 2016]; 54(6):1033-1038. Disponible en: http://www.jaad.org/article/S0190-9622%2806%2900551-2/abstract

  35. Edwards L, Levine N, Weidner M, Piepkorn M, Smiles K. Effect of intralesional interferon in actinic keratoses. Arch Dermatol.1986 [citado 7 mar 2016]; 122(7):779-782.Disponible en: http://jamanetwork.com/journals/jamadermatology/article-abstract/547332

  36. Edwards L, Levine N, Smiles KA. The effect of topical interferon alfa 2b on actinic kerotoses. J Dermatol Surg Oncol. 1990 [citado 7 mar 2016]; 16(5):446-449.Disponible en: http://onlinelibrary.wiley.com/doi/10.1111/j.1524-4725.1990.tb00062.x/abstract

  37. González Cabañas R, Ferrero Bibilonia J, Morales Menéndez MG, Aguilera Rodríguez A, López Saura P. Inmunogenicidad del interferón alfa-2b recombinante (Heberón alfa R®). Detección de anticuerpos mediante un ensayo inmunoenzimático y neutralización de actividad antiviral. Biotecnología Aplicada. 1998[citado 7 mar 2016]; 15(2):71-76.Disponible en: http://elfosscientiae.cigb.edu.cu/PDFs/Biotecnol%20Apl/1998/15/2/071-076.pdf

  38. Torres Rives B, Miranda Moles A, García García I, Porreo Martín J, Nodarse Cuní H. Evaluación de la Inmunogenicidad del Interferón alfa 2b humano recombinante en pacientes con Hepatitis crónica y Hemangiomas de la infancia. Rev Habanera Cien Méd.2005 [citado 7 mar 2016]; 4(5): Disponible en:http://www.revhabanera.sld.cu/index.php/rhab/article/view/840/658

  39. Soler Arus E, Velázquez Infante M, Padrón Guillermo J, Menéndez Morales M G, Oramas Bienvenido G. et. al. Interferón alfa-2b recombinante en hepatitis C crónica: Resultados del tratamiento y determinación de anticuerpos anti-interferón. Biotecnología Aplicada. 1997[citado 7 mar 2016]; 14(4):242-247. Disponible en: http://elfosscientiae.cigb.edu.cu/PDFs/Biotecnol%20Apl/1997/14/4/242-247.pdf




2020     |     www.medigraphic.com